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An effect of thyroid hormone (TH) on erythropoiesis has been
known for more than a century but the molecular mechanism(s)
by which TH affects red cell formation is still elusive. Here we
demonstrate an essential role of TH during terminal human
erythroid cell differentiation; specific depletion of TH from the
culture medium completely blocked terminal erythroid differenti-
ation and enucleation. Treatment with TRβ agonists stimulated
premature erythroblast differentiation in vivo and alleviated ane-
mic symptoms in a chronic anemia mouse model by regulating ery-
throid gene expression. To identify factors that cooperate with TRβ
during human erythroid terminal differentiation, we conducted
RNA-seq in human reticulocytes and identified nuclear receptor
coactivator 4 (NCOA4) as a critical regulator of terminal differentia-
tion. Furthermore, Ncoa4−/− mice are anemic in perinatal periods
and fail to respond to TH by enhanced erythropoiesis. Genome-
wide analysis suggests that TH promotes NCOA4 recruitment to
chromatin regions that are in proximity to Pol II and are highly
associated with transcripts abundant during terminal differentia-
tion. Collectively, our results reveal the molecular mechanism by
which TH functions during red blood cell formation, results that
are potentially useful to treat certain anemias.
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The production of red blood cells (RBCs) in mammals istightly regulated by erythropoietin (Epo), a kidney-produced
hormone that stimulates erythropoiesis by promoting the survival,
proliferation, and terminal differentiation of colony-forming unit
erythroid (CFU-E) progenitors (1, 2). The early phase of CFU-E
erythroid differentiation is Epo dependent, whereas later stages
are Epo independent (3). Binding of Epo to Epo receptors (EpoRs)
on the surface of erythroid progenitors such as CFU-Es leads to
the activation of multiple intracellular signal transduction path-
ways, including those mediated by signal transducer and activator
of transcription 5 (Stat5) and phosphatidylinositide 3-kinase (PI-3
kinase), which are essential for erythroid progenitor survival and
proliferation (4, 5).
A group of hormones that bind to and activate nuclear re-
ceptor (NR) transcription factors (TFs) also regulate erythro-
poiesis. Cortisol and its receptor glucocorticoid receptor (GR)
are important during stress erythropoiesis and synthetic gluco-
corticoids have been used to treat severe anemias such as Diamond
Blackfan anemia (DBA) (6–8). Corticosteroids promote the self-
renewal of burst-forming unit erythroid (BFU-E) progenitors and
prevent their differentiation to the more mature CFU-Es (9, 10).
The GR synergizes with peroxisome proliferator-activated receptor
alpha (PPAR-α) to enhance BFU-E self-renewal, and PPAR-α
agonists and corticosteroids increase red blood cell production both
in cell culture and in vivo (11). Retinoid acid increases the numbers
of human erythroid progenitors, including BFU-Es in vitro (11).
Retinoid acid receptor alpha (Rxra) knockout mice are anemic
during the embryonic period due to a deficiency in erythroid dif-
ferentiation, although the molecular mechanism(s) is still unclear
(12). In addition, the orphan nuclear receptors, testicular receptors
2 and 4 (TR2/TR4), are involved in globin switching in adult ery-
throid cells (13).
A function of TH in erythropoiesis has been known for more
than a century (14, 15). Aberrant production of RBCs and
anemia are often observed in patients with thyroid diseases (16).
TH signals through TH nuclear receptors α (TRα) and β (TRβ),
both possessing different splicing isoforms (17). Although the
molecular mechanism(s) underlying TH function on erythro-
poiesis is unknown, human genome-wide association studies
(GWASs) have identified genetic variances in the TRβ locus
associated with abnormal hematological traits (18). Knocking
out TRα but not TRβ in mice results in reduction in the numbers
of early erythroid progenitors in fetal livers (19).
Here we demonstrate that TH is required for terminal ery-
throid differentiation. Targeting thyroid hormone signaling by
TH receptor agonists enhances the differentiation of erythroid
progenitors. More importantly, treatment with TRβ agonist GC-
1 enhanced erythroblast differentiation in vivo and alleviated
anemic symptoms in a chronic anemia mouse model. Further-
more, we identified NCOA4 as a critical component of TH sig-
naling during erythroid terminal differentiation. Genome-wide
analysis suggested that TH promotes NCOA4 recruitment
to chromatin regions that are in proximity to Pol II and are
highly associated with genes encoding transcripts that are
abundant during terminal differentiation. Our results reveal the
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molecular mechanism by which TH stimulates terminal red
blood cell formation, results that are potentially useful to treat
certain anemias.
Results
TH Is Required for Terminal Erythroid Differentiation. To test whether
TH is essential for human red blood cell formation, we used a
four-stage culture system using human CD34+ peripheral blood
hematopoietic stem/progenitor cells purified from G-CSF–treated
normal individuals (11). Terminal differentiation requires serum
and begins at day (D) 14 when Epo is the only cytokine added to
the culture medium. Replacement of normal FBS at day 14 with
charcoal-stripped FBS completely blocked terminal differentia-
tion, as measured by the percentage of enucleated cells (Fig. 1A).
Consistent with a block in erythroid development, the size of
erythroid cells cultured with charcoal-stripped FBS is signifi-
cantly larger than that of the control group. Importantly, addi-
tion of thyroxine (T4) at day 14 completely rescued the failure of
terminal differentiation of erythroid cells by charcoal-stripped
FBS (Fig. 1A).
T4 also accelerates and enhances terminal erythroblast dif-
ferentiation when added at day 14 to normal cultures (Fig. S1A),
leading to over ∼95% enucleation at day 16, while control cells
in these human CD34+ erythroid cultures have not begun to
enucleate (Fig. 1B and Fig. S1B). Consistent with premature in-
duction of terminal differentiation, treatment of mouse BFU-Es
with T4 rapidly induced expression of erythroid genes such as
Hemoglobin Beta Chain (Hbb), Solute Carrier Family 4, Anion
Exchanger, Member 1) (Slc4a1), Ferritin Light Chain (Ftl), and
Alpha Hemoglobin Stabilizing Protein (Ahsp), and reduced the
expression of Kit, which is essential for erythroid progenitor self-
renewal and is normally down-regulated during terminal differ-
entiation (Fig. S1C). These data reinforce the essential function
of TH in promoting terminal erythroid differentiation.
While both TRα and TRβ proteins are expressed in human
CD34+ progenitors, only TRβ protein is detectable in late eryth-
roblasts (Fig. 1C). Knocking down TRβ in CD34+ cells impaired
the enucleation of human erythroblasts, indicating that TRβ is
required for human erythroid terminal differentiation (Fig. 1D).
Consistent with the notion that TRβ but not TRα is required for
terminal differentiation, both T4 and the TRβ selective agonist
GC-1 restore normal erythroblast differentiation, measured by
enucleation, that is deficient in cultures in charcoal-stripped serum
(Fig. S1D). These effects of TH receptor (THR) agonists are
significantly abrogated upon TRβ knockdown (Fig. S1D). Taken
together, these data suggest that TH is required for terminal dif-
ferentiation of human erythroid progenitors and that this function
is mediated by TRβ and not TRα.
Global run-on sequencing (GRO-seq) analysis showed up-
regulation of many erythroid genes including HBB, Hemoglobin
Alpha Chain (HBA), and SLC4A1 in human erythroblasts treated
with GC-1 (Fig. 1E). In contrast, expression of genes involved in
the cell cycle and essential for stem/progenitor self-renewal and
normally down-regulated during terminal erythropoiesis, including
KIT, MYB, and PPARA (11), were significantly down-regulated by
GC-1 treatment. Together, these studies showed that activation of
TRβ accelerates terminal human erythroid differentiation.
TRβ Agonist GC-1 Alleviates Anemia in a Chronic Anemia Mouse
Model. We tested whether TRβ selective agonists are able to in-
crease red cell production in a mouse model of chronic anemia,
neonatal anemia (Nan) mice (20). GC-1 injection significantly in-
creased hemoglobin levels, hematocrits, and RBC numbers, and
reduced the numbers of reticulocytes in these anemic mice (Fig.
2A). Red cells in Nan/+ mice are anisocytotic with many micro-
cytes, spherocytes, and hypochromic cells (20). These abnormalities
were alleviated by GC-1 treatment (Fig. 2B). Quantitatively, the
red blood cell distribution width (RDW) was significantly increased
above normal in Nan/+ mice, and the RDW was significantly
decreased, although not to normal, following GC-1 treatment
(Fig. 2C). These data suggest TH alleviates anemic symptoms in
these mice through enhancing erythroid differentiation.
In mice the spleen is the primary site of stress erythropoiesis
(21). Both spleen size and weight were dramatically increased in
Nan/+ mice (20) (Fig. S2 A and B). GC-1 injection reduced both
splenomegaly and spleen weight in Nan/+ mice compared with
control DMSO treatment (Fig. S2B). Colony-forming assays
showed that GC-1–injected mice had fewer BFU-E progenitors
in the spleen, suggesting that indeed GC-1 is able to alleviate
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Fig. 1. TH promotes terminal erythroid differentiation through TRβ.
(A) Human CD34+ cells from G-CSF mobilized peripheral blood were cultured
by the four-stage (21 d total) erythroid differentiation method as described
in Materials and Methods. At day 14, cells were switched to terminal dif-
ferentiation (Dif III) culture medium containing serum, stripped serum, or
stripped serum supplemented with 1 μM T4. Flow cytometry analysis was
conducted at day 21. (Bottom Right) Forward scatterplots are shown for
erythroid cells at day 21. (B) Benzidine-Giemsa staining demonstrating cell
morphology of human erythroblasts at day 16 of the CD34+ erythroid cul-
ture. Brown color of benzidine staining indicates hemoglobin accumulation.
Cells were untreated or treated with 1 μM T4 at day 14 for 72 h. (C) Western
blotting demonstrating protein levels of TRα and TRβ in human erythroid
cells at days 9 and 15 of culture. (D) Human CD34+ cells were transduced by
lentivirus vectors encoding shRNAs targeting either LacZ (control) or THRB at
day 1. (Top) Protein expression of TRβ determined by Western blotting at
day 14. (Bottom) The percentage of enucleated cells was determined by flow
cytometry analysis at day 21. (E) Gene expression in human erythroid cells
untreated or treated at day 14 with 1 μM GC-1 for 6 h is analyzed by GRO-
seq. Data were normalized to cells treated with DMSO (error bars represent
mean ± SD from three independent experiments. *P < 0.05, **P < 0.01,
***P < 0.001).
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stress erythropoiesis in vivo (Fig. S2C). In Nan/+ mice virtually
all of the spleen cells are positive both for CD71 and Ter119,
indicating that they are in the erythroid lineage. Treatment with
GC-1 reduced this population significantly such that about half
the cells are negative both for CD71 and Ter119 and thus pre-
sumably not undergoing erythroid differentiation (Fig. S2D).
Thus, GC-1 not only alleviates the anemia characteristic of the
Nan/+ mice, it also reduces extramedullary erythropoiesis.
We next set out to understand how TH receptor agonist
GC-1 increases RBC production in Nan/+ mice. Nan/+ BFU-E
cells were isolated from embryonic day 14.5 (E14.5) fetal livers
and cultured for 6 h in the presence or absence of GC-1. Con-
sistent with previous studies, Eklf mRNA levels as well as levels
of mRNAs encoding Dmtn, Slc4a1, and Hbb, were significantly
down-regulated in cells from Nan/+ mice compared with those
from WT littermates (20). Treatment with GC-1 significantly
increased the expression of Dmtn, Slc4a1, and Hbb (20) (Fig.
S2E). In contrast, GC-1 did not increase the expression of Eklf or
Gata1. Therefore, our data suggested TH alleviates anemia in the
Nan/+ mice by up-regulating expression of several key erythroid-
important genes.
NCOA4 Is Essential for Human Erythroblast Terminal Differentiation.
To further determine which transcriptional regulators are im-
portant for terminal erythropoiesis, we isolated reticulocytes
produced in our culture of human adult CD34+ stem/progenitor
cells (11). RNA-seq analysis on these cells (Fig. S3A) revealed an
abundance of NCOA4 transcripts. Recently NCOA4 has been
suggested to regulate iron metabolism during mouse erythro-
poiesis (22–26). However, the function of NCOA4 has not been
tested in primary human erythroblasts, and our experiments,
detailed below, suggest important nuclear functions of NCOA4.
Initial studies showed that the protein level of NCOA4 in both
nucleus and cytoplasm is increased during terminal differentia-
tion (Fig. 3A), and the NCOA4 transcript level is immediately
up-regulated by GC-1 in human erythroid cells (Fig. 1E).
Knocking down NCOA4 in human erythroblasts impaired
human erythroid terminal differentiation in normal media (Fig.
S3B). Similarly, knockdown of NCOA4 blocked the enhancement
of erythroid differentiation induced by GC-1 treatment of erythroid
cultures placed in charcoal-stripped serum to remove thyroxine
(Fig. 3B). RNA-seq analysis revealed that NCOA4 knockdown re-
duced induction of erythroid genes whose activation was dependent
on activation of STAT5 downstream of activated Epo receptors
(Fig. S3C). Knockdown of NCOA4 also prevented the normal
down-regulation of hypoxia-induced genes during terminal differ-
entiation, genes that are important for erythroid progenitor self-
renewal and that are normally down-regulated during terminal
differentiation (Fig. S3C). We also validated our RNA-seq data by
real-time PCR analysis (Fig. S3D), showing impaired induction of
key erythroid-important genes following Ncoa4 knockdown. More
generally, genes up-regulated by at least 1.5-fold in human eryth-
roblasts upon GC-1 treatment (Fig. 1E) were mostly down-
regulated following NCOA4 knockdown (Fig. 3C). In contrast,
genes normally down-regulated by more than 50% during terminal
differentiation were mostly up-regulated by NCOA4 knockdown,
suggesting an essential role of NCOA4 during erythroid terminal
differentiation regulated by TH (Fig. 3C). Taken together, these
data suggest that NCOA4 is important for TH signaling during
human erythroid terminal differentiation by regulating erythroid
gene expression; these functions are additional to any relating to
iron metabolism (22–26).
NCOA4 Is Recruited by THR Agonist GC-1 to Genomic Loci of Many
Erythroid Genes. We thus hypothesized that NCOA4 is a key
transcriptional regulator during terminal erythropoiesis. ChIP-seq
analysis established that 12.8% of the NCOA4 chromatin binding
sites are associated with transcriptional start sites (TSSs) and 8.4%
are in 5′-UTR regions (Fig. S4A). Treatment with GC-1 signifi-
cantly increased the signal intensities of the top 300 NCOA4
chromatin binding sites, which overlapped with binding sites for
Pol II as well as with histone marks associated with active tran-
scription, such as H3K27Ac and H3K4Me3, but not with marks
such as H3K4Me1 commonly associated with enhancers (Fig. 4A).
As many of these chromatin binding “peaks” are close to TSS
segments, slightly downstream of TSSs, we hypothesized that
NCOA4 is recruited in response to TH treatment to regulate
gene transcription in erythroblasts. Supporting this notion, these
chromatin binding sites are associated with abundant transcripts
(<3 kb from TSSs) in human reticulocytes (Fig. S4B). Associa-
tion of NCOA4 in the proximity of TSSs increased signifi-
cantly in response to TH (Fig. 4B). As examples, enrichment of
NCOA4 signals at chromatin sites in several erythroid-important
gene loci such as HBB, SLC4A1, and HBA was more pronounced
upon GC-1 treatment, and this enrichment was highly associated
with the occupancy of Pol II in these regions (Fig. 4C and Fig.
S4C). Interestingly, DNA sequences underlying NCOA4 peaks
are enriched in DNA binding motifs for several transcription
factors including TRβ (Fig. S4D). Therefore, our data suggest
NCOA4 is highly associated with genomic regions of many ery-
throid genes and might regulate expression of these genes to-
gether with Pol II and other transcription factors, including TRβ.
Ncoa4 Knockout (Ncoa4−/−) Mice Are Anemic and Fail to Respond to
TH Treatment.Among all seven members of the Ncoa gene family,
only the Ncoa4 gene locus is associated with strong active
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Fig. 2. TRβ agonist alleviates anemic symptoms in a chronic anemia mouse
model. (A) Nan/+ mutant mice, 6∼8 wk old, were injected with TRβ agonist
GC-1 (500 μg/kg) daily for 11 d. Hemoglobin (HGB), red blood cell numbers
(RBCs), hematocrit (HCT), reticulocytes, white blood cells (WBCs), and
platelets were measured on day 0 (open circles) and day 11 (black circles).
WBCs and platelets ofWT mice (brown circles) at the same ages were included.
Each dot represents onemouse. (B) Peripheral blood smears fromWT andNan/+
mice treated with GC-1 at day 0 or day 11. Blood samples from the two Nan/+
mice (nos. 1 and 2) were collected individually for analysis at D0 or D11 after the
GC-1 injection for comparison. Blood samples frommice injected with DMSO for
11 d were included as control. (C) Red blood cell distribution width (RDW) of
WT, or GC-1–treated Nan/+mice on day 0 and day 11. *P < 0.05, ****P < 0.0001.
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transcription markers in mouse Ter119+ erythroblasts (27) (Fig.
S5A). Although previous studies suggested that Ncoa4 is im-
portant for erythropoiesis, the function of Ncoa4 has not been
validated in primary erythroblasts (22–26). Knocking down
Ncoa4 but not any other Ncoa tested impaired terminal eryth-
ropoiesis in our mouse erythroid culture (Fig. S5 B and C). We
next generated Ncoa4−/− mice using the CRISPR-Cas method
(Fig. 5A). Consistent with previous reports (24–26), Ncoa4−/−
mice were anemic during the immediate postnatal period (Fig.
5B). Erythroid progenitors were also significantly reduced in
bone marrow (Fig. 5C). Moreover, GC-1 injection did not alle-
viate the anemia of Ncoa4−/− mice (Fig. 5D), supporting the
notion that Ncoa4 is required for TH signaling. GC-1 failed to
induce erythroid gene expression in BFU-Es purified from
Ncoa4−/− fetal livers (Fig. 5E). Taken together, these data sug-
gest that Ncoa4 is essential for TH function in erythropoiesis.
Discussion
Anemia has long been observed in hypothyroidism and in pa-
tients resistant to thyroid hormone (RTH) (14, 28, 29), and a
stimulatory effect of TH on erythropoiesis has been well docu-
mented (16, 30). Several studies showed that TH significantly en-
hances the number of erythroid progenitor BFU-Es and CFU-Es
in cultured cells from both human and canine marrow. However,
due in part to the cellular complexity of bone marrow (31), the
stage(s) of erythropoiesis and the molecular mechanism(s) by
which TH stimulates red cell production has remained obscure.
In addition, GWASs identified human genetic variants in the
TRβ locus that are associated with abnormal hematocrits (18)
and mutations in the THRB gene are common in RTH patients
with anemia (32).
Here we established, first, that TH is essential for terminal
human erythropoiesis, and functions through the TRβ receptor.
Consistent with a key role for TRβ, both TH and the specific
TRβ agonist GC-1 stimulate red cell formation in a mouse model
of chronic anemia by stimulating erythroid gene expression. GC-
1 also stimulated terminal erythropoiesis in our human erythroid
cell culture system.
Thrb knockout mice exhibit normal erythropoiesis (19), whereas
knocking out TRα resulted in a reduction in the numbers of early
erythroid progenitors in fetal livers (19). Consistent with a role of
TRα in early stages of erythroid development, our results showed
that TRα protein levels are much higher in early human progenitors
compared with late stage erythroblasts. Similarly, overexpression of
TRα in murine erythroid progenitors supported sustained growth of
these cells and prevented erythroid differentiation (33). It will be
interesting to examine red cell production in Thrb knockout mice
during erythroid stress, as earlier BFU-E progenitors play a key role
in stress erythropoiesis (21).
Abnormal levels of TH are present in several types of anemia
patients, and some anemia patients have been treated with
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synthetic TH (8, 34). Our results demonstrate that injection of the
TRβ selective agonist GC-1 alleviated anemia in a chronic anemia
mouse model. GC-1 not only raised hemoglobin levels, hemato-
crits, and red blood cell numbers, but also reduced stress eryth-
ropoiesis and anisocytosis of the Nan mice in vivo. The increase of
red cells by GC-1 is likely due to a direct function on bone marrow
erythroid cells (35). Selective TRβ agonists like GC-1 not only can
effectively treat metabolic diseases such as dyslipidemia, athero-
sclerosis, and obesity, but also have a promising safety profile (36,
37). Thus, these data suggest that GC-1 or other selective TRβ
agonists might be used to treat certain anemias due to deficiencies
in erythroid differentiation (38, 39).
Nuclear receptor signaling often requires cooperation with
coactivators and corepressors. Our loss-of-function studies in hu-
man erythroblasts, together with our analysis of Ncoa4−/− knock-
out mice, established that coactivator NCOA4 is essential for red
blood cell formation. NCOA4 was first discovered as a coactivator
of the androgen receptor (40). NCOA4 transcripts are highly
abundant in hematopoietic cells, particularly the erythroid lineage
(23). Ncoa4−/− knockout mice are anemic in embryos and in the
early postnatal period, but eventually acquire normal levels of red
cells, similar to what we observed in Stat5a−/−5b−/− knockout mice,
where the mice greatly increased the numbers of erythroid pro-
genitors (41). Both NCOA4 loss-of-function assays in human
erythroblasts and in mice demonstrated impaired TH signaling
during terminal erythroid differentiation. Importantly, our ChIP-
seq data revealed that NCOA4 is bound to chromatin in close
proximity to Pol II and is recruited to many erythroid gene loci to
regulate their expression in response to TH signaling during ter-
minal erythroid differentiation. We detected TRβ binding motifs
within NCOA4-associated genomic regions, together with binding
motifs for other TFs. This indicates TRβ might form a complex
with NCOA4 and possibly other factors to regulate gene ex-
pression. However, due to the inefficiency of TRβ antibodies in
coimmunoprecipitation and ChIP-seq experiments, we could not
yet determine the physical interaction or the colocalization on
chromatin between NCOA4 and TRβ.
Interestingly, recent studies also suggest that NCOA4 might
play other roles in regulating red cell formation. NCOA4 is pre-
sent in autophagosomes and interacts with ferritin heavy and light
chains and facilitates the delivery of ferritin into lysosomes under
stress conditions (24, 25). Dowdle et al. (25) observed profound
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Fig. 5. Ncoa4−/− mice are anemic during both embryonic and perinatal periods and fail to respond to thyroxin treatment to promote erythropoiesis.
(A) Schematic outline of Cas9/sgRNA-targeting in the Ncoa4 gene. The sgRNA-targeting sequence is shown. The protospacer-adjacent motif (PAM) sequence is
highlighted in red. Nine nucleotides (underlined) are eliminated and 116 nucleotides are inserted into the site. Western blotting showing mouse
NCOA4 protein expression in bone marrow of WT and Ncoa4 KO mice. (B) Hemoglobin measurement of mice with indicated genotypes. +/+, wild-type; Ncoa4+/−,
heterozygous; Ncoa4−/−, homozygous. Each dot represents measurement from one mouse. ****P < 0.0001. (C) Colony-forming assays were conducted to de-
termine BFU-E and CFU-E colony numbers from 105 bone marrow cells of wild-type, Ncoa4+/−, or Ncoa4−/− mice. Error bars represent mean ± SD from three
biological replicates; *P < 0.05, **P < 0.01. (D) Hematological analysis of Ncoa4 KO mice treated with DMSO (control, white circles) or GC-1 (black circles). Blood
samples were collected from individual mice at D0 and D11 after the treatment. Each dot represents a measurement from one mouse. (E) Real-time PCR analysis
of erythroid gene expression in WT and Ncoa4−/− mouse BFU-Es treated or untreated with GC-1. Mouse BFU-E cells were isolated from WT and Ncoa4−/− mouse
embryos. BFU-Es were treated with or without GC-1 for 6 h. Actin beta gene (Actb) is shown as a control.
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accumulation of iron in splenic macrophages in Ncoa4 KO mice
(24, 25). Mancias et al. (26) reported that knocking out Ncoa4
impairs hemoglobin formation in zebrafish and K562 cells.
In summary, our results have elucidated the molecular mecha-
nisms by which TH functions to support terminal red blood cell
formation and suggested that targeting TRβ by its selective ago-
nists can potentially be used to treat certain types of anemias.
Materials and Methods
Reagents. Details of the reagents are described in SI Materials and Methods.
Ex Vivo Human CD34+ Erythroid Culture. The human CD34+ cell erythroid
differentiation method comprises four phases over 21 d: Expansion (days 0–
4), differentiation (Dif) I (days 5–9), II (days 10–13), and III (days 14–21) as
described before (11) and in SI Materials and Methods.
Global Run-On Sequencing. GRO-seq experiments were performed as pre-
viously reported (42) and detailed in SI Materials and Methods.
Genotyping of Nan/+ Mice Embryos. The Nan/+ mice were a gift from Luanne
Peters, The Jackson Laboratory, Bar Harbor, ME. Nan/+ mice were mated to
wild-type littermates. Individual embryos at E14.5 d were genotyped as
described previously and in SI Materials and Methods. All mouse procedures
were approved by the Animal Care and Use Committees of the Massachusetts
Institute of Technology.
ChIP-Seq and de Novo Motif Discovery. ChIP-seq experiments in human
erythroblast cells were conducted as described before (11) and in SI Materials
and Methods.
RNA-Seq and Quantitative Real-Time RT-PCR. The procedures were conducted
as described in SI Materials and Methods.
Generation of Ncoa4 Knockout Mice. The procedures of in vitro transcription of
Cas9 mRNA and sgRNA, one-cell embryo injection, and knockout mice
genotyping are described in SI Materials and Methods.
Immunoblotting. The procedures were conducted as described in SI Materials
and Methods.
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